Croda International Plc operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Croda International Plc with three other
companies in this sector in the United Kingdom:
sales of £839.48 million [US$1.10 billion]
of which 100%
was Buprenorphine Based Drugs),
Hikma Pharmaceuticals PLC
(£1.49 billion [US$1.96 billion]
of which 40%
was Injectable Pharmaceuticals), and
(£570.50 million [US$750.66 million]
of which 38%
was Interventional Medicine).
Croda International Plc reported sales of £1.37 billion (US$1.81 billion)
December of 2017.
increase of 10.4%
versus 2016, when the company's sales were £1.24 billion.
This was the third consecutive year of growth at Croda International Plc.
Sales of Performance Technologies saw an increase
13.5% in 2017, from
£402.50 million to £456.90 million.
Not all segments of Croda International Plc experienced an increase in sales in 2017:
sales of Industrial Chemicals fell 1.0% to £127.00 million.